Solid Tumors Clinical Trial
Official title:
A Phase I Study of a Novel Chemotherapeutic Regimen: Topotecan, Ifosfamide and Carboplatin (TIC) in Children and Young Adults With Solid Tumors-- A Limited Multi-Institution Study
Primary Objectives:
- To determine the maximum tolerated dose (MTD) of Topotecan when added to a fixed dose
regimen of Ifosfamide and Carboplatin in children and young adults with solid tumors.
- To evaluate the toxicity associated with the administration of Topotecan with
Ifosfamide and Carboplatin (TIC) in children and young adults with solid tumors.
Secondary Objectives:
- To evaluate the duration of neutropenia (ANC<500/micro L) and thrombocytopenia (PLT
50,000/ micro L and 20,000/ micro L) and the number of days of platelet transfusion
during each course of TIC chemotherapy when used in conjunction with G-CSF and NEUMEGA
in children and young adults with solid tumors.
- To determine the median number of apheresis collections as well as the CD34/kg,
CD41/kg, CD61/kg and CD34:41/kg and CD34:61/kg per collection in patients electively
undergoing concurrent apheresis for peripheral blood stem cell collection in courses 2
or 3.
- To determine the median number of peripheral blood mononuclear cells (PBMC) and ex-vivo
expanded myeloid dendritic cells (DC) in patients electively undergoing concurrent
apheresis for PBMC collection in courses 2 or 3.
All of the chemotherapy drugs used in this study are FDA approved and commercially available
drugs designed to kill cancer cells.
Before you can start treatment on this study, you will have what are called "screening
tests". These tests will help the doctor decide if you are eligible to take part in the
study. You will have a physical exam and routine blood (about 2 teaspoons) and urine tests.
You will have electrocardiogram (ECG - test to measure the electrical activity of the
heart). You will have a chest x-ray and other scans (such as CT, MRI, Bone, Ultrasound or
radionucleotide scans ). You physician will decide which scans are appropriate based on the
disease and clinical situation. You will also have a bone marrow aspirate. To collect a bone
marrow aspirate, an area of the hip or chest bone is numbed with anesthetic and a small
amount of bone marrow is withdrawn through a large needle. Women who are able to have
children must have a negative pregnancy test before starting treatment.
If you are found to be eligible to take part in this study, you will be assigned to a
specific dose of topotecan. The first group of participants will receive a smaller dose of
topotecan. If patients in that group are able to recover a sufficient number of platelets by
Day 22 and no severe side effects are experienced, the next group of participants will be
treated with a larger dose topotecan. The dose will continue to be increased for each new
group of participants until all the participants in a dose group are unable to recover a
sufficient number of platelets by Day 22, or until severe side effects are experienced.
There will be 3 patients in each group. The doses of all the other drugs used on this study
will be the same for every participants.
Topotecan, ifosfamide, and carboplatin will be given for the first three days of each
course. Ifosfamide and carboplatin will be given into a vein for one hour each day along
with the drug mesna. Mesna is not an anti-cancer drug but a drug to help protect the bladder
from the potential damaging effects of ifosfamide. After the first dose of mesna,
participants will receive 3 more doses (one every three hours) over 15-30 minutes .
Topotecan is given directly into a vein for one-half hour beginning one hour after treatment
with ifosfamide, carboplatin, and the first dose of mesna is completed. Participants who are
22 years or older will only receive Day 1 and 2 of carboplatin.
Starting on the fourth day of each course, you will be given a daily injection of the drug
Filgrastim. Filgrastim is a growth factor naturally produced in the body to stimulate the
production of white blood cells (infection fighting cells). Filgrastim can now be produced
in the laboratory and given to patients at higher doses than the body makes. Filgrastim
should help the body recover from treatment. Filgrastim will be given as an injection under
the skin once a day until an acceptable number of white blood cells are detected in the
bloodstream.
A second course of chemotherapy will begin as soon as 21 days after the start of treatment
as long as you have recovered enough white blood cells and platelets. If the white blood
cells and platelets have not recovered by 21 days, you will begin the next course when they
do recover.
After each of the first three courses, you will have a re-evaluation of the disease.
Re-evaluation will require the same scans to be performed as were done at study entry. If
the tumor shows a complete or partial response to the treatment after the second course,
then continuation on the study will be at the discretion of the treating physician. If the
disease is stable, meaning there is no change in the size or degree of the tumor, then
treatment can continue for a total of 3 courses overall.
If the disease gets worse or intolerable side effects occur, you will be taken off study and
other treatment options will be discussed with you.
You may need to be hospitalized during the first three days of each chemotherapy course and
will require visits as an outpatient at other times during treatment to receive laboratory
follow-up and evaluation. Participants may also require hospitalization because of side
effects.
During treatment, you will have a physical exam and routine blood (about 2 teaspoons) and
urine tests. You will also have an ECG, a chest x-ray, and other scans as thought necessary.
The physical exam will be done once a week for Courses 1 - 3. The blood tests will be done
on Days 1, 3, 5; then twice weekly and on Day 22 of each course. Urine tests will be done on
Day 1 of each course and at the end of Course 2. The scans and ECG will be performed at the
end of each course or sooner if it is suspected that the disease has gotten worse.
This is an investigational study. The drugs on this study are FDA approved and commercially
available. However, their use together in this study is experimental. Up to 78 patients will
take part in this study. About 15 patients will be enrolled at UTMDACC.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
| Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
| Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
| Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
| Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
| Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
| Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
| Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 |